Kinzalmono

Telmisartan, the active ingredient in Kinzalmono, is an Angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and related cardiovascular risk in adult patients.

GNH USA supplies Kinzalmono as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Telmisartan is an ARB used to manage conditions related to the renin‑angiotensin system.

- Hypertension: lowers blood pressure and reduces the risk of cardiovascular events. - Cardiovascular risk reduction: helps decrease the incidence of stroke and myocardial infarction in high‑risk patients. - Diabetic nephropathy: slows the progression of kidney damage in individuals with type 2 diabetes.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Back pain - Upper respiratory tract infection

Serious or Rare Side Effects: - Angioedema - Acute renal impairment - Hyperkalemia - Symptomatic hypotension - Hepatic injury

Before initiating therapy, consider the following safety measures.

- Monitor renal function: assess serum creatinine and eGFR at baseline and periodically. - Check electrolytes: especially potassium levels during treatment. - Use caution in hepatic impairment: adjust therapy if significant liver disease is present. - Avoid in patients with known hypersensitivity to telmisartan or other ARBs. - Store at room temperature: keep in the original container, protect from moisture and light.

Telmisartan may interact with several medicines; clinical judgement is required.

Major Interactions (Avoid): - Aliskiren (in diabetic patients): increased risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: heightened risk of hyperkalemia. - ACE inhibitors: combined use may raise the incidence of angioedema. - NSAIDs: can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance hypotensive response. - Lithium: telmisartan can raise lithium concentrations, requiring monitoring. - CYP2C9 inhibitors (e.g., fluconazole): may increase telmisartan exposure and necessitate dose adjustment.